Abstract: Early stopping of clinical trials either in the case of beneficial or deleterious effect of treatment on quality of life (QoL) is an important issue. QoL is usually evaluated using self-assessment questionnaires and responses to the items are combined into scores assumed to be normally distributed (which is rarely the case). An alternative is to use item response theory (IRT) models such as the partial credit model (PCM) for polytomous items which takes into account the categorical nature of the items.
Introduction
Many clinical trials attempt to measure health-related quality of life (QoL) which refers to 'the extent to which one's usual or expected physical, emotional and social well-being are affected by a medical condition or its treatment' [Cella and Bonomi (1995) and Fairclough (2002) ]. QoL endpoints, reflecting the patient's perception of his or her well-being and satisfaction with therapy, are important health outcomes to consider. However, each domain of health can have several components (e.g., symptoms, ability to function, disability) and translating these various domains of health into quantitative values to measure quality of life is a complex task, drawing from the field of psychometrics, biostatistics, and clinical decision theory. In clinical trials in which specific therapeutic interventions are being studied, QoL is usually evaluated using self-assessment questionnaires that consist of a set of questions called items, which are often polytomous and frequently combined to give scores for scales or subscales. The common practice is to work on average scores that are generally assumed to be normally distributed. However, these average scores are rarely normally distributed and usually do not satisfy a number of basic measurement properties including sufficiency, unidimensionality, or reliability. Moreover, these scores are often used as a reduction of a larger amount of data without introducing clearly the mechanism of such reduction in the likelihood.
Item response theory (IRT), which was first mostly developed in educational testing, takes into account the multiplicity and categorical nature of the items by introducing an underlying response model [Fisher and Molenaar (1995) ] relating those items to a latent parameter having the nice property to be interpreted as the true individual QoL. In this framework, the probability of response of a patient on an item depends upon two different parameters: the 'ability level' of the person (which reflects his or her current QoL) and the 'difficulty' of the item (which reflects somehow the capacity of that specific item in discriminating between good and bad QoL).
QoL endpoints are often studied in noncomparative phase II trials, which are commonly designed to evaluate therapeutic efficacy as well as further investigation of the side-effects and potential risks associated with therapy. Early stopping of clinical trials either in the case of beneficial or deleterious effect of the treatment on QoL is an important matter [Cannistra (2004) ]. Several early termination procedures, allowing for repeated statistical analyses on accumulating data and for stopping a trial as soon as the information is sufficient to conclude, have been developed over the last few decades [Jennison and Turnbull (1999) and Whitehead (1997) ]. Although sequential methodology is often used in clinical trials, IRT modelling, as a tool for scientific measurement, is not quite well established in the clinical trial framework despite a number of
